Dr. Rini on the Axitinib and Sorafenib Trial VEGF Focus

Video

Dr. Brian Rini from Taussig Cancer Institute explains the Axitinib and Sorafenib AXIS Trial VEGF Potency Focus

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, explains the vascular enthothelial growth factor (VEGF) potency and comparison explored in the AXIS 1032 phase III trial comparing axitinib to sorafenib (both VEGF inhibitors) in the second-line setting for metastatic renal cell carcinoma (mRCC).

Dr. Rini says many doctors had a hypothesis that the agents that are more potent and selective against the VEGF receptor family, which is the major therapeutic receptor in kidney cancer, would produce clinical benefits. Up until now, there was no comparative data to support or refute that hypothesis. The AXIS 1032 phase III trial study, by in essence comparing a more potent versus a less potent VEGF inhibitor, provides data to say there is a clinical advantage to that biochemical drug advantage. Dr. Rini adds that other studies with other settings and other drugs are needed to flesh out the story, but the theme is becoming clearer as more clinical data is collected.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute